Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.19.1
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
STOCKHOLDERS' DEFICIT

NOTE 8 – STOCKHOLDERS’ EQUITY 


Common stock issued for exercise of warrants


During the first quarter of 2019, the Company entered into an agreement with two current shareholders who were also holders of warrants to purchase shares of common stock in the aggregate amount of 3,000,000 shares, to reduce the exercise price of these warrants to $0.55 from the original exercise price of $0.65 based on immediate exercise. Both shareholders exercised these warrants in March 2019 for proceeds to the Company of $1,650,000.


Stock-Based Compensation


Stock-based compensation expense recognized under ASC 718-10 for the three months ended March 31, 2019, was $21,892 for stock options granted to employees and directors. This expense is included in selling, general and administrative expenses in the unaudited consolidated statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. At March 31, 2019, the total compensation cost for stock options not yet recognized was $88,784. This cost will be recognized over the remaining vesting term of the options of approximately 1 year.


On January 29, 2019, the Board of Directors appointed a new independent director and Chairman of the Compensation Committee. As a result of the appointment, the new director was granted 120,000 stock options exercisable at $1.00 per share vesting one year from the date of grant.


Employee Stock Options


A maximum of 2,500,000 shares were made available for grant under the 2016 Plan, as amended, and all outstanding options under the Plan provide a cashless exercise feature. The identification of individuals entitled to receive awards, the terms of the awards, and the number of shares subject to individual awards, are determined by our Board of Directors or the Compensation Committee, at their sole discretion. The aggregate number of shares with respect to which options or stock awards may be granted under the 2016 Plan and the purchase price per share, if applicable, shall be adjusted for any increase or decrease in the number of issued shares resulting from a stock dividend, stock split, reverse stock split, recapitalization or similar event. As of March 31, 2019, and December 31, 2018, options to purchase 2,362,000 and zero shares of common stock were outstanding under the 2016 Plan, respectively.


The Company has no expired employee stock options under the 2016 Plan at March 31, 2019.


 

 

 

 

 

March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

Exercise

 

 

 

 

 

 

 

 

 

Shares

 

 

Price

 

Outstanding at beginning of year

 

 

 

 

 

 

 

 

 

 

—

 

 

$

—

 

Granted

 

 

 

 

 

 

 

 

 

 

2,362,000

 

 

$

1.00

 

Exercised

 

 

 

 

 

 

 

 

 

 

—

 

 

$

—

 

Forfeited

 

 

 

 

 

 

 

 

 

 

—

 

 

$

—

 

Expired

 

 

 

 

 

 

 

 

 

 

—

 

 

$

—

 

Outstanding at March 31, 2019

 

 

 

 

 

 

 

 

 

 

2,362,000

 

 

$

1.00

 

Exercisable at March 31, 2019

 

 

 

 

 

 

 

 

 

 

1,956,000

 

 

$

1.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average remaining contractual term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.25

 

Aggregate intrinsic value

 

 

 

 

 

 

 

 

 

 

 

 

 

$

—

 

Weighted average grant date fair value (per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

0.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average remaining contractual term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.25

 

Aggregate intrinsic value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

—

 


Warrants


The following is a summary of activity for warrants to purchase common stock for the three months ended March 31, 2019:


 

 

March 31, 2019

 

 

 

Number of Warrants

 

 

Weighted

Avg.

Exercise

Price

 

 

Remaining Contractual Life (Years)

 

Outstanding at the beginning of the year

 

 

25,538,551

 

 

$

.70

 

 

 

3.9

 

Warrants expired

 

 

—

 

 

 

 

 

 

 

 

 

Warrants issued

 

 

—

 

 

 

 

 

 

 

 

 

Warrants cancelled/exercised

 

 

(3,000,000

)

 

 

 

 

 

 

 

 

Outstanding at end of period

 

 

22,538,551

 

 

 

.63

 

 

 

3.6

 

Exercisable at end of period

 

 

22,538,551

 

 

$

.63

 

 

 

3.6

 


During the first quarter of 2019, the Company received $1,650,000 for the exercise of warrants for 3,000,000 shares of common stock.